TY - JOUR
T1 - Resting cell neutralization assay for HIV-1 primary isolates
AU - Hioe, Catarina
AU - Burda, Sherri
AU - Chigurupati, Padmasree
AU - Xu, Serena
AU - Zolla-Pazner, Susan
N1 - Funding Information:
This work was supported in part by a VA Merit Review grant, by the Research Center for AIDS and HIV Infection (RCAHI) of the Department of Veterans Affairs, and by NIH Grants AI32424 and AI36085. C.E.H. was supported by NIH AIDS Institutional Training Grant AI07382. The authors thank Dr. Cecilia Dayaraj for helpful discussion and Ms. Laurie Kaye for assistance with the preparation of the manuscript.
PY - 1997/8
Y1 - 1997/8
N2 - A technique is described for detecting the activity of neutralizing polyclonal or monoclonal antibodies against HIV-1 primary isolates. Most commonly, neutralizing antibody activity for HIV-1 is assessed by quantifying the ability of antibodies to inhibit virus infection in mitogen-activated peripheral blood mononuclear cells or transformed lymphocytes. Because the target of HIV infection in vivo is neither a mitogen-activated nor a transformed cell, an assay using unstimulated peripheral blood mononuclear cells as a more physiologic target cell was developed. This 'resting cell assay' mainly utilizes primary HIV-1 isolates that have been carried for only a few passages in vitro. The result is an assay that is more efficient to perform and that detects neutralizing activity with comparable or greater sensitivity than that previously described for assays of primary HIV-1 isolates.
AB - A technique is described for detecting the activity of neutralizing polyclonal or monoclonal antibodies against HIV-1 primary isolates. Most commonly, neutralizing antibody activity for HIV-1 is assessed by quantifying the ability of antibodies to inhibit virus infection in mitogen-activated peripheral blood mononuclear cells or transformed lymphocytes. Because the target of HIV infection in vivo is neither a mitogen-activated nor a transformed cell, an assay using unstimulated peripheral blood mononuclear cells as a more physiologic target cell was developed. This 'resting cell assay' mainly utilizes primary HIV-1 isolates that have been carried for only a few passages in vitro. The result is an assay that is more efficient to perform and that detects neutralizing activity with comparable or greater sensitivity than that previously described for assays of primary HIV-1 isolates.
UR - https://www.scopus.com/pages/publications/0031215044
U2 - 10.1006/meth.1997.0483
DO - 10.1006/meth.1997.0483
M3 - Article
C2 - 9245610
AN - SCOPUS:0031215044
SN - 1046-2023
VL - 12
SP - 300
EP - 305
JO - Methods
JF - Methods
IS - 4
ER -